A new vaccine for Europe
A new vaccine (“Nuvaxovid”) from the American biotech company Novavax has been approved by the European Medicines Agency (EMA).
A new vaccine (“Nuvaxovid”) from the American biotech company Novavax has been approved by the European Medicines Agency (EMA).
The mission of the Vigilance and Protection against Foreign Digital Interference (Viginum) service is to protect the democratic debate from external intrusions. By better monitoring internal publications?
In its response to the Ministry of Health, the National Consultative Ethics Committee (CCNE) approved, today, the opening of vaccination against Covid-19 to all children aged 5 to 11. But 62% of the parents would be hostile to it, according to a poll BVA/RTL.
Should we change our vaccination strategy since mass vaccination with two, three and soon four doses fails to eradicate the Covid-19 epidemic? The scientific controversy is growing.
The scientific community speaks out against the health policy of the authorities: the declaration of Great Barrington (USA) against massive injections of mRNA has collected 870.000 signatures.
Jean-Marc Sabatier, Director of Research at the CNRS and Doctor of Cell Biology and Microbiology, has doubts about mandatory vaccination. Because vaccines have lost their initial effectiveness. And the Omicron variant, although contagious, does not cause serious forms of the disease.
But what do we really know about this variant? Is it more contagious, more dangerous? The molecular analysis of Jacques Fantini, professor of Biochemistry and Molecular Biology at the University of Aix-Marseille.
Highly contagious, this new variant impacts the financial markets and calls into question the vaccine strategy since the current vaccines are designed to counter the initial Wuhan strain which has completely disappeared.
The European Medicines Agency (EMA) approves this November 25, 2021 the vaccination of children aged 5 to 11 years. A “crazy decision” for many scientists. Who will be legally responsible?
Emerging in China in November 2019, SARS-CoV-2 has killed more than five million people and infected 258 million. And it’s not over. A look back at two years of global health crisis.
Two scientists, Dr. Jean-Marc Sabatier and Prof. Jacques Fantini*, explain why the third vaccine dose can have serious long-term side effects due to the “ADE” phenomenon (Antibody-dependent enhancement: facilitation of infection by antibodies). The benefit/risk ratio would be unfavorable. Explanations
The result of scientific work carried out over the last 3 years by teams from the Nancy CHRU (Centre d’Investigation Clinique – Plurithématique) and Loria, e’VM is a new tool for predicting the risk of heart failure.